CVP chemo followed by Bexxar RIT produces impressive results in small study

The inaugural issue of the ASCO Post has been published, and its lead story concerns the long-term efficacy of radioimmunotherapy in patients with follicular lymphoma (FL). Specifically, this concerns the use of combination chemotherapy (CVP) followed by Bexxar.

COHORT

The multi-center study in question enrolled 30 US patients over age 18 who had been diagnosed with CD20-positive untreated stage III, IV, or bulky (tumor diameter ~ 5 em) stage II, low-grade FL.

Call

DETAILS

Patients received six cycles of CVP chemotherapy on a 21 day cycle. (To remind our readers, CVP chemotherapy is similar to the more familiar CHOP therapy—the chief difference being that CVP excludes the anthracycline doxorubicin, making the combination safer for the patient's heart and lungs).

Tositumomab and l31I-tositumomab (Bexxar) were initiated within 56 days after day 1 of the sixth cycle of CVP.

All patients completed therapy according to plan.

Additionally, twenty-six patients received a 75-cGy dose of total-body radiation and the other four received a 65-cGy dose of total-body radiation.

RESULTS

Median follow-up: 8.4 years.

Response rates following the six cycles of CVP:
Complete response (CR) rate: 53%.
Partial response (PR) rate: 47%
Overall response (OOR) rate: 100%

After finishing the Bexxar phase, response rates were:
Complete response (CR) rate: 93%.
Overall response (ORR) rate: 100%

Additionally, six of the patients ultimately died of FL.

CONCLUSIONS

Said senior author John P Leonard, "These 8 year follow-up data show that CVP followed by radioimmunotherapy is a highly active first-line therapy for FL … [they] are the first description of sequentially combining 131-I radioimmunotherapy following CVP."

However, readers should take note of two competing aspects of this study: The first is the small number of patients. 30 patients is way too small to draw any significant and reliable conclusions about the efficacy of this therapy; what it really is good for is for encouraging continued research into it. On the other hand, the response rates are very encouraging, and they contribute to the growing body of peer-reviewed evidence that radioimmunotherapy is a safe, effective and viable means of fighting such a prevalent but notoriously hard-to-treat indolent cancer like FL.

By Ross Bonander

Sources:
- The ASCO Post Volume 1, Issue 1, June 2010
- Link BK et al. "Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: Eight-year follow-up of a multicenter phase II study." J Clin Oncol. May 10, 2010

Call

More Articles

More Articles

This entry looks at Non Hodgkin's Lymphoma in the lungs, clinically known as pulmonary lymphoma, one of the subtypes of lymphoma. 'Lymphoma' is an...

In order to prevent developing any subtype of lymphoma, it would be helpful to know the causes of lymphoma. Unfortunately, in virtually every case...

BEAM chemotherapy is an acronym representing a small family of combination chemotherapy regimens that are used chiefly as salvage regimens in the...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

The Erythrocyte Sedimentation Rate (ESR - sometimes called sed rate or sedimentation rate) is a nonspecific screening test for various...

Blood counts can be used to identify disease and monitor patient health during cancer treatments. Though these tests cannot diagnose lymphoma on...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is effective against extranodal natural killer/T-cell...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Patients treated with maintenance rituximab had three times longer progression-free survival. This is a summary of an article published in the...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...

Since so many chemotherapy agents can affect a patient’s sex drive and fertility, thinking about these issues prior...